Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Sarcoma 3Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Prolactinoma 1Pituitary Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Central Nervous System Neoplasms 1Adenoma, Chromophobe 1Adenoma, Basophil 1Adenoma, Acidophil 1

Interventions

selpercatinib 2Cisplatin 2pentetreotide 1pembrolizumab 1entrectinib 1cabozantinib 1budigalimab 1amino-acid, glucose, and electrolyte solution 1Temozolomide 1Tamoxifen 1Surveys and Questionnaires 1Rosiglitazone 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Microarray Analysis 1Immunotherapy 1Drug Therapy 1Doxorubicin 1DNA Methylation 1Carboplatin 1Biological Therapy 190Y-octreotide, DOTA-Tyr(3)- 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Microarray Analysis × Endocrine × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡